William Blair Reaffirms Outperform Rating for OptimizeRx (NASDAQ:OPRX)

OptimizeRx (NASDAQ:OPRX)‘s stock had its “outperform” rating reiterated by William Blair in a research report issued on Thursday,RTT News reports.

A number of other research firms also recently weighed in on OPRX. Barclays reduced their price target on shares of OptimizeRx from $11.00 to $5.00 and set an “equal weight” rating on the stock in a research note on Thursday. Royal Bank of Canada cut their target price on shares of OptimizeRx from $14.00 to $7.00 and set an “outperform” rating on the stock in a research report on Thursday. B. Riley began coverage on shares of OptimizeRx in a research report on Thursday, July 25th. They set a “buy” rating and a $18.50 target price on the stock. Roth Mkm reiterated a “buy” rating and set a $16.00 target price (down from $20.00) on shares of OptimizeRx in a research report on Thursday. Finally, JMP Securities cut their target price on shares of OptimizeRx from $16.00 to $8.00 and set a “market outperform” rating on the stock in a research report on Thursday. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, OptimizeRx currently has an average rating of “Moderate Buy” and an average target price of $10.42.

OptimizeRx Trading Down 5.8 %

OPRX opened at $3.83 on Thursday. The company’s 50 day moving average is $6.60 and its 200-day moving average is $8.99. OptimizeRx has a 1-year low of $3.78 and a 1-year high of $16.65. The company has a current ratio of 3.07, a quick ratio of 3.07 and a debt-to-equity ratio of 0.27. The company has a market cap of $70.07 million, a P/E ratio of -2.88 and a beta of 1.32.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Rice Hall James & Associates LLC raised its holdings in OptimizeRx by 24.0% during the third quarter. Rice Hall James & Associates LLC now owns 615,441 shares of the company’s stock worth $4,751,000 after buying an additional 119,306 shares during the last quarter. Renaissance Technologies LLC grew its stake in shares of OptimizeRx by 101.8% in the 2nd quarter. Renaissance Technologies LLC now owns 142,146 shares of the company’s stock worth $1,421,000 after acquiring an additional 71,700 shares in the last quarter. Vanguard Group Inc. grew its stake in shares of OptimizeRx by 0.6% in the 1st quarter. Vanguard Group Inc. now owns 1,027,293 shares of the company’s stock worth $12,482,000 after acquiring an additional 6,291 shares in the last quarter. First Light Asset Management LLC grew its stake in shares of OptimizeRx by 5.1% in the 2nd quarter. First Light Asset Management LLC now owns 1,826,961 shares of the company’s stock worth $18,270,000 after acquiring an additional 89,377 shares in the last quarter. Finally, Squarepoint Ops LLC bought a new stake in shares of OptimizeRx in the 2nd quarter worth $282,000. Institutional investors and hedge funds own 76.47% of the company’s stock.

About OptimizeRx

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.